help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DEFOUILLOY, C.
Right arrow Articles by ADNOT, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DEFOUILLOY, C.
Right arrow Articles by ADNOT, S.

Am. J. Respir. Crit. Care Med., Volume 157, Number 5, May 1998, 1452-1460

Polycythemia Impairs Vasodilator Response to Acetylcholine in Patients with Chronic Hypoxemic Lung Disease

CHRISTIAN DEFOUILLOY, EMMANUEL TEIGER, SAID SEDIAME, PIERRE ANDRIVET, FRANÇOISE ROUDOT-THORAVAL, CHRISTOS CHOUAID, BRUNO HOUSSET, and SERGE ADNOT

Département de Physiolgie et Institute National de la Sante et de la Recherche Medicale U296; Hôpital Henri Mondor, Créteil, France

To investigate whether polycythemia associated with chronic hypoxemic lung disease (CHLD) increases vascular resistance by altering endothelium-derived nitric oxide (NO), we examined the responses to acetylcholine (ACh) infusions (5, 10, and 15 mg/min) on hemodynamics and gas exchange in 21 patients with CHLD of varying severity. Patients were classified into two groups based on whether their hemoglobin (Hb) level was less or greater than 15.5 g/dl. In the normocythemic patients (Hb = 13.6 ± 0.3 g/100 ml, n = 10), ACh decreased pulmonary artery pressure (Ppa) from 30 ± 2 mm Hg 26 ± 2 mm Hg (p < 0.01); pulmonary vascular resistance (PVR), from 5.1 ± 0.4 U/m2 to 3.4 ± 0.3 U/m2 (p < 0.001); systemic arterial pressure (Psa), from 111 ± 4 mm Hg to 108 ± 4 mm Hg (p < 0.05); and systemic vascular resistance (SVR), from 27 ± 2 U/m2 to 22 ± 2 U/m2 (p < 0.01); and also increased the cardiac index (CI), from 3.8 ± 0.2 to 4.7 ± 0.3 L/min/m2 (p < 0.001). PaO2 fell from 59 ± 3 mm Hg to 48 ± 3 mm Hg (p < 0.001) whereas venous admixture (Qs/Qt) rose from 32 ± 4% to 44 ± 4% (p < 0.01). In contrast, in patients with polycythemia (17.7 ± 0.5 g/100 ml, n = 11) ACh failed to produce any changes in PaO2 (49 ± 2 mm Hg versus 51 ± 2 mm Hg, p = NS), Ppa (34 ± 1 mm Hg versus 33 ± 1 mm Hg, p = NS), PVR (6.7 ± 0.9 U/m2 versus 6.9 ± 0.8 U/m2, p = NS) or Psa, but slightly increased the CI, from 3.6 ± 0.3 L/min/m2 to 3.9 ± 0.3 L/min/m2 (p < 0.01), and Qs/Qt, from 40 ± 4% to 45 ± 3% (p < 0.05). In the 21 patients, negative correlations with Hb concentrations were found for ACh-induced changes in PVR (r = -0.57, p < 0.01), Ppa (r = -0.46, p < 0.01), CI (r = -0.5, p < 0.05), PaO2 (r = -0.79, p < 0.01), and Qs/Qt (r = -0.79, p < 0.01). In the six polycythemic patients who received isovolemic hemodilution, with a decrease in Hb concentration from 18.6 ± 0.9 g/dl to 15.3 ± 0.3 g/dl as a result, infusion of ACh, which was without effect before hemodilution, caused decreases in Ppa from 28 ± 1 mm Hg to 23 ± 1 mm Hg (p < 0.05) and in PVR from 5.7 ± 0.8 U/m2 to 3.6 ± 0.5 U/m2 (p < 0.02), as well as an increase in CI from 3.4 ± 0.4 L/min/ m2 to 4.1 ± 0.4 L/min/m2 (p < 0.05). In contrast to ACh, inhaled NO (40 ppm) induced pulmonary vasodilation in both the normocythemic and polycythemic groups. Our results show that high hematocrit (Hct) levels inhibit endothelium-dependent vasodilation in response to ACh in patients with CHLD, possibly through inactivation of endothelial-derived NO by Hb.




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
S. EDDAHIBI, M. HUMBERT, S. SEDIAME, C. CHOUAID, C. PARTOVIAN, B. MAITRE, E. TEIGER, D. RIDEAU, G. SIMONNEAU, O. SITBON, et al.
Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension . Effect of Prostacyclin Therapy
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1493 - 1499.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society
  ATS 2008 State of the Art Course